Oligonucleotide Synthesis Market worth $32.72 billion by 2031 – Exclusive Report by MarketsandMarkets™

at PR Newswire

DELRAY BEACH, Fla., July 16, 2026 /PRNewswire/ — According to MarketsandMarkets™, the Oligonucleotide Synthesis Market is projected to reach USD 32.72 billion by 2031 from USD 14.64 billion in 2026, at a CAGR of 17.4% during the forecast period.

MarketsandMarkets Logo (PRNewsfoto/MarketsandMarkets)

Browse 600 market data tables and 78 figures spread through 460 pages and in-depth TOC on the “Oligonucleotide Synthesis Market – Global Forecast to 2031”

Oligonucleotide Synthesis Market Size & Forecast:

  • Market Size Available for Years: 2026–2031
  • 2026 Market Size: USD 14.64 billion
  • 2032 Projected Market Size: USD 32.72 billion
  • CAGR (2026–2032): 17.4%

Oligonucleotide Synthesis Market Trends & Insights:

  • The fundamental shift from chemical small molecules to advanced biotechnology therapies is significantly disrupting the oligonucleotide synthesis market. Over the forecast period from 2026 to 2031, traditional synthesis boundaries are increasingly dissolving as high-growth therapeutic areas—specifically oncology, precision neurology, and cardiovascular diseases—necessitate highly complex, long-chain oligonucleotides. This development is inducing substantial disruptions across related biological sectors: next-generation gene therapies are requiring custom-engineered single-guide RNAs, metagenomic sequencing is compelling the production of extensive parallel custom libraries, and mRNA-based therapeutic vaccines are scaling to commercial volumes. Consequently, synthesis providers must strategically transition from legacy laboratory-scale chemistries to high-throughput platforms capable of supporting these diverse macromolecular pipelines.
  • By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2025, at ~71.5%.
  • In the oligonucleotide synthesis products market, by type, the reagents & consumables segment accounted for the largest share in 2025, at ~92.1%.
  • By end user, the specialty clinics segment accounted for the largest share of the market in 2025, at ~44.7%.
  • The North American oligonucleotide synthesis market was dominant in 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

Key drivers of market growth include rising demand for oligonucleotide-based drugs such as ASOs and siRNAs to treat neurological and rare disorders, including Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and hepatic veno-occlusive disease (VOD), as well as technological advancements in oligonucleotide synthesis.

Advancements in oligonucleotide synthesis, such as enzymatic de novo methods and continuous-flow technologies, have improved production efficiency and scalability. Regulatory bodies are adapting to these innovations. For instance, the FDA’s draft guidance on nonclinical safety assessment for oligonucleotide-based therapeutics, published in November 2024, provides a framework for evaluating safety profiles, while the EMA’s draft guideline addresses manufacturing and analytical controls for synthetic oligonucleotides. These developments have coincided with increased regulatory approvals, as over 17 oligonucleotide therapeutics have received FDA approval, underscored their growing utility and signaling a transformative period for the oligonucleotide synthesis market.

By type, the antisense oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.

By type, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2025, the ASOs (antisense oligonucleotide-based drugs) segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. They have seen rapid clinical and commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst and investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines.

In 2025, the hospitals segment accounted for the largest share of the oligonucleotide-based drugs market.

By end user, the oligonucleotide-based drugs market includes hospitals, specialty clinics, home care settings, and other end users. In 2025, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to rising demand for oligonucleotide-based drugs for rare and neurological diseases, primarily driven by an increasing target patient population. This segment’s significant share reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious and chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=200829350

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America accounted for the largest share of the oligonucleotide synthesis market, owing to the presence of strong regional players with advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals under supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region’s expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers to scale up production are also expected to be growth drivers for this regional segment.

Key Players

Leading players in the Oligonucleotide Synthesis companies include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=200829350

Browse Adjacent Market: Biotechnology Market Research Reports & Consulting

See More Latest Biotechnology Reports:

Molecular Diagnostics Market  by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) – Global Forecast to 2030

Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition – Global Forecast to 2031

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/oligonucleotide-synthesis-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/oligonucleotide-synthesis.asp

 

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/oligonucleotide-synthesis-market-worth-32-72-billion-by-2031—exclusive-report-by-marketsandmarkets-302827425.html